natural altern - NAII

NAII

Close Chg Chg %
1.18 0.02 1.69%

Open Market

1.20

+0.02 (1.69%)

Volume: 64.20

Last Updated:

Oct 26, 2026, 9:30 AM EDT

Company Overview: natural altern - NAII

NAII Key Data

Open

$1.20

Day Range

1.20 - 1.20

52 Week Range

1.08 - 4.95

Market Cap

$7.53M

Shares Outstanding

6.28M

Public Float

5.15M

Beta

0.36

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$3.42

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

30.86K

 

NAII Performance

1 Week
 
0.00%
 
1 Month
 
-30.86%
 
3 Months
 
-49.58%
 
1 Year
 
-55.60%
 
5 Years
 
-90.40%
 

NAII Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About natural altern - NAII

Natural Alternatives International, Inc. engages in the manufacturing, distribution, and marketing of nutritional supplements and other health care products. It operates through the Private-Label Contract Manufacturing, and Patent and Trademark Licensing segments. The Private-Label Contract Manufacturing segment provides manufacturing services to companies that market and distribute nutritional supplements and other health care products. The Patent and Trademark Licensing segment is involved in direct raw material sales and royalty income from license and supply agreements associated with the sale and use of beta-alanine. The company was founded by Mark A. LeDoux in 1980 and is headquartered in Carlsbad, CA.

NAII At a Glance

Natural Alternatives International, Inc.
1535 Faraday Avenue
Carlsbad, California 92008
Phone 1-760-736-7700 Revenue 141.35M
Industry Pharmaceuticals: Other Net Income -20,695,000.00
Sector Health Technology 2026 Sales Growth 9.084%
Fiscal Year-end 06 / 2027 Employees 230
View SEC Filings

NAII Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.102
Price to Book Ratio 0.30
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.076
Enterprise Value to Sales 0.403
Total Debt to Enterprise Value 0.878

NAII Efficiency

Revenue/Employee 614,578.261
Income Per Employee -89,978.261
Receivables Turnover 6.845
Total Asset Turnover 0.92

NAII Liquidity

Current Ratio 1.735
Quick Ratio 0.92
Cash Ratio 0.198

NAII Profitability

Gross Margin 5.543
Operating Margin -6.41
Pretax Margin -14.336
Net Margin -14.641
Return on Assets -13.469
Return on Equity -34.962
Return on Total Capital -20.709
Return on Invested Capital -19.546

NAII Capital Structure

Total Debt to Total Equity 100.028
Total Debt to Total Capital 50.007
Total Debt to Total Assets 35.437
Long-Term Debt to Equity 77.604
Long-Term Debt to Total Capital 38.796
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Natural Altern - NAII

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
157.02M 113.85M 129.58M 141.35M
Sales Growth
-6.52% -27.50% +13.82% +9.08%
Cost of Goods Sold (COGS) incl D&A
142.94M 106.93M 120.57M 133.52M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.08M 4.65M 4.56M 4.71M
Depreciation
7.08M 4.65M 4.56M 4.71M
Amortization of Intangibles
- - - -
-
COGS Growth
-3.01% -25.19% +12.76% +10.74%
Gross Income
14.09M 6.92M 9.01M 7.84M
Gross Income Growth
-31.61% -50.88% +30.25% -13.05%
Gross Profit Margin
+8.97% +6.08% +6.95% +5.54%
2023 2024 2025 2026 5-year trend
SG&A Expense
4.74M 15.20M 16.15M 16.90M
Research & Development
2.10M 1.90M 1.80M 2.30M
Other SG&A
2.64M 13.30M 14.35M 14.60M
SGA Growth
-51.21% +220.65% +6.25% +4.63%
Other Operating Expense
- - - 1.42M
-
Unusual Expense
200.00K 200.00K 1.80M 10.85M
EBIT after Unusual Expense
7.72M (8.48M) (8.94M) (19.91M)
Non Operating Income/Expense
(3.71M) (622.00K) (887.00K) 835.00K
Non-Operating Interest Income
33.00K 176.00K 168.00K 50.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
451.00K 361.00K 915.00K 1.19M
Interest Expense Growth
+443.37% -19.96% +153.46% +29.62%
Gross Interest Expense
451.00K 361.00K 915.00K 1.19M
Interest Capitalized
- - - -
-
Pretax Income
3.56M (9.46M) (10.74M) (20.27M)
Pretax Income Growth
-73.97% -366.22% -13.48% -88.69%
Pretax Margin
+2.26% -8.31% -8.29% -14.34%
Income Tax
1.03M (2.25M) 2.83M 430.00K
Income Tax - Current - Domestic
1.05M (14.00K) 3.94M 10.37M
Income Tax - Current - Foreign
221.00K 66.00K 161.00K 455.00K
Income Tax - Deferred - Domestic
(242.00K) (2.23M) (1.27M) (10.39M)
Income Tax - Deferred - Foreign
- - - (69.00K)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.52M (7.22M) (13.57M) (20.70M)
Minority Interest Expense
- - - -
-
Net Income
2.52M (7.22M) (13.57M) (20.70M)
Net Income Growth
-76.46% -386.16% -88.10% -52.45%
Net Margin Growth
+1.61% -6.34% -10.48% -14.64%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.52M (7.22M) (13.57M) (20.70M)
Preferred Dividends
- - - -
-
Net Income Available to Common
2.52M (7.22M) (13.57M) (20.70M)
EPS (Basic)
0.4302 -1.2293 -2.2828 -3.4332
EPS (Basic) Growth
-75.43% -385.75% -85.70% -50.39%
Basic Shares Outstanding
5.86M 5.87M 5.95M 6.03M
EPS (Diluted)
0.4291 -1.2293 -2.2828 -3.4332
EPS (Diluted) Growth
-75.34% -386.48% -85.70% -50.39%
Diluted Shares Outstanding
5.88M 5.87M 5.95M 6.03M
EBITDA
15.00M (3.63M) (2.58M) (4.35M)
EBITDA Growth
-15.69% -124.22% +29.06% -68.81%
EBITDA Margin
+9.55% -3.19% -1.99% -3.08%

Insider Actions for Natural Altern - NAII

Date Name Shares Transaction Value
Mar 11, 2026 Mark A. LeDoux CEO/Chairman; Director 156,737 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.73 per share 427,892.01
Mar 11, 2026 Mark A. LeDoux CEO/Chairman; Director 176,737 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Kenneth Eugene Wolf President, COO, & Sec. 126,831 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.73 per share 346,248.63
Mar 11, 2026 Kenneth Eugene Wolf President, COO, & Sec. 141,831 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Alan G. Dunn Director 99,211 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Guru Ramanathan Director 38,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Laura Kay Matherly Director 42,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Michael E. Fortin Chief Financial Officer 46,554 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.73 per share 127,092.42
Mar 11, 2026 Michael E. Fortin Chief Financial Officer 58,554 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Natural Altern in the News